Clareo Health | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
This study consists of two periods:
1. An induction period which will test the induction of clinical remission;
2. An optional active treatment extension (ATE) period which will explore durability of clinical response and remission in which all participants will receive vixarelimab.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of UC for at least 3 months
Moderately to severely active UC, assessed by mMS
Inadequate response, loss of response to, or intolerance to conventional or advanced therapies for UC
You may not be if
Diagnosis of Crohn's disease or indeterminate colitis
Suspicion of ischemic, radiation, microscopic, or infectious colitis
Prior colectomy
Inadequate response or loss of response to previous treatment of UC with tofacitinib, upadacitinib, or other systemic janus kinase (JAK) inhibitor
